Concepedia
Statistics
Publications
40
Citations
3.9K
H-Index
25
Active since
1986
Affiliations
Memorial Sloan Kettering Cancer Center(Current)
Foundation Medicine (United States)
Albany Medical Center Hospital
Cornell University
Vanderbilt University
V.A. Miller is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and molecular oncology.
Publications per year
1986–2019
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Francis M. Sirotnak, Maureen F. Zakowski, V.A. Miller et al. · PubMed · 2000 · 762 citations
Medicine, Oncology, Pharmacology +15
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
Alexa B. Schrock, Ching Ouyang, Jaideep Sandhu et al. · Annals of Oncology · 2019 · 628 citations
Medicine, Immunology, Oncology +17
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Christian Grommes, Geoffrey R. Oxnard, Mark G. Kris et al. · Neuro-Oncology · 2011 · 343 citations · Full text
Medicine, Oncology, Pharmacology +17
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing
Christine H. Chung, Violeta Beleva Guthrie, David L. Masica et al. · Annals of Oncology · 2015 · 204 citations · Full text
Medicine, Oncology, Pathology +16
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
V.A. Miller, Arabinda K. Das, M. Rossi · Journal of Clinical Oncology · 2009 · 193 citations
Medicine, Oncology, Pharmacotherapy +8
1–5 of 40